The ultrastructural study of tumorigenic cells using nanobiomarkers.
Despite recent advances, patients with malignant brain tumors still have a poor prognosis. Glioblastoma (WHO grade 4 astrocytoma), the most malignant brain tumor, represents 50% of all astrocytomas, with a median survival rate of <1 year. It is, therefore, extremely important to search for new diagnostic and therapeutic approaches for patients with glioblastoma. This study describes the application of superparamagnetic nanoparticles of iron oxide, as well as monoclonal antibodies, of immunophenotypic significance, conjoined to quantum dots for the ultrastructural assessment of glioblastoma cells. For this proposal, an immunophenotypic study by flow cytometry was carried out, followed by transmission electron microscopy analysis. The process of tumor cell labeling using nanoparticles can successfully contribute to the identification of tumorigenic cells and consequently for better understanding of glioblastoma genesis and recurrence. In addition, this method may help further studies in tumor imaging, diagnosis, and prognostic markers detection.
Pavon
Lorena Favaro
LF
Instituto do Cérebro, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil. lorenap@einstein.br
Marti
Luciana Cavalheiro
LC
Sibov
Tatiana Tais
TT
Malheiros
Suzana M F
SM
Oliveira
Daniela Mara
DM
Guilhen
Daiane Donna
DD
Camargo-Mathias
Maria Izabel
MI
Amaro Junior
Edson
E
Gamarra
Lionel Fernel
LF
D000071916:AC133 Antigen; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D015703:Antigens, CD / Q000276:immunology / Q000378:metabolism; D015415:Biomarkers / Q000032:analysis / Q000737:chemistry; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism; D002467:Cell Nucleus / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D022162:Cytoplasmic Vesicles / Q000378:metabolism; D004705:Endocytosis / Q000276:immunology; D000071063:Endoglin; D005434:Flow Cytometry; D000072278:Forkhead Box Protein M1; D051858:Forkhead Transcription Factors / Q000737:chemistry / Q000378:metabolism; D005909:Glioblastoma / Q000175:diagnosis* / Q000378:metabolism / Q000648:ultrastructure*; D006023:Glycoproteins / Q000276:immunology / Q000378:metabolism; D006801:Humans; D018960:Hyaluronan Receptors / Q000276:immunology / Q000378:metabolism; D016130:Immunophenotyping; D019012:Integrin beta1 / Q000276:immunology / Q000378:metabolism; D058185:Magnetite Nanoparticles / Q000737:chemistry; D046529:Microscopy, Electron, Transmission; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry; D010455:Peptides / Q000276:immunology / Q000378:metabolism; D045663:Quantum Dots; D011956:Receptors, Cell Surface / Q000276:immunology / Q000378:metabolism; D013194:Staining and Labeling / Q000379:methods*; D014407:Tumor Cells, Cultured
D000071916:AC133 Antigen; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015415:Biomarkers; C497483:CD44 protein, human; C064206:ENG protein, human; D000071063:Endoglin; C107585:FOXM1 protein, human; D000072278:Forkhead Box Protein M1; D051858:Forkhead Transcription Factors; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D019012:Integrin beta1; D058185:Magnetite Nanoparticles; D010455:Peptides; D011956:Receptors, Cell Surface